Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge.
Journal Information
Full Title: J Clin Virol
Abbreviation: J Clin Virol
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:
"Declaration of Competing Interest Dr. Bierle and Dr. Ganesh have nothing to disclose. Dr. Razonable is principal investigator of research funded by Regeneron, Roche, Gilead (all funds provided to his institution), and is a member of Data Safety Monitoring Board of Novartis, on projects not directly related to this submission. Dr. Razonable received research funds from the Mayo Clinic for studies on monoclonal antibodies for COVID-19."
Funding Disclosure
Evidence found in paper:
"Funding Mayo Clinic"
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025